MDT-AP-1152
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 65.03999999999999
- os_event
- false
- age_years
- 1.8
- sex
- M
- new_clusters
- S2
- umap1_2d
- -1.729149906
- umap2_2d
- -8.854384474
- umap1_3d
- -2.99066517
- umap2_3d
- -1.594984574
- umap3_3d
- 5.007713472
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.680
- INTERFERON_GAMMA_RESPONSE+0.570
- IL6_JAK_STAT3_SIGNALING+0.550
- ALLOGRAFT_REJECTION+0.490
- INFLAMMATORY_RESPONSE+0.470
- TNFA_SIGNALING_VIA_NFKB+0.450
- COAGULATION+0.410
- KRAS_SIGNALING_UP+0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.380
- IL2_STAT5_SIGNALING+0.360
Top 10 suppressed
- E2F_TARGETS-0.600
- G2M_CHECKPOINT-0.600
- MYC_TARGETS_V1-0.580
- MITOTIC_SPINDLE-0.460
- OXIDATIVE_PHOSPHORYLATION-0.460
- MYC_TARGETS_V2-0.450
- UNFOLDED_PROTEIN_RESPONSE-0.450
- DNA_REPAIR-0.440
- PROTEIN_SECRETION-0.440
- MTORC1_SIGNALING-0.410
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | sclcA055A_S52.txt | — | cohortMD2 | 0.967 |
| 2 | sclc55A_S50.txt | — | cohortMD2 | 0.947 |
| 3 | TCGA-44-A47G-01A-21R-A24H-07 | — | cohortA1 | 0.936 |
| 4 | BS_3H71BH6Q | Ganglioglioma | — | 0.935 |
| 5 | TCGA-99-8028-01A-11R-2241-07 | — | cohortMD2 | 0.934 |
| 6 | TCGA-A2-A0CO-01A-13R-A22K-07 | — | A | 0.934 |
| 7 | TCGA-D8-A73U-01A-11R-A33J-07 | — | D | 0.933 |
| 8 | sclc0617_S65.txt | — | cohortMD2 | 0.932 |
| 9 | TCGA-69-8453-01A-12R-2326-07 | — | cohortA1 | 0.931 |
| 10 | BS_R244Z0WX | pilocytic astrocytoma | — | 0.930 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 28 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.680 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.570 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.550 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.490 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.470 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.450 | Inavolisib | — uncovered |
| COAGULATION | 0.410 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.400 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.380 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.360 | Idelalisib | — uncovered |
| MYOGENESIS | 0.360 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.340 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.330 | Temsirolimus | — uncovered |
| APOPTOSIS | 0.330 | Idelalisib | — uncovered |
| COMPLEMENT | 0.330 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.320 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.280 | Inavolisib | — uncovered |
| HYPOXIA | 0.260 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.260 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.200 | Remibrutinib | — uncovered |